Woodline Partners’s UroGen Pharma URGN Stock Holding History

Woodline Partners’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$18.4M	Hold	500,726	–	–	0.06%	385
2026 Q1	$9M	Hold	500,726	–	–	0.03%	539
2025 Q4	$11.7M	Buy	500,726 +194,355	+63%	+$4.22M	0.05%	420
2025 Q3	$6.11M	Sell	306,371 -353	-0.1%	-$6.34K	0.03%	527
2025 Q2	$4.2M	Buy	306,724 +353	+0.1%	+$3.39K	0.02%	597
2025 Q1	$3.39M	Buy	306,371 +729	+0.2%	+$7.77K	0.02%	591
2024 Q4	$3.26M	Hold	305,642	–	–	0.02%	572
2024 Q3	$3.88M	Buy	305,642 +1,902	+0.6%	+$28.2K	0.03%	418
2024 Q2	$5.1M	Buy	+303,740	New	+$4.32M	0.05%	335

Other funds holding URGN

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Woodline Partners's URGN Position: Q2 2026 in Review

Woodline Partners held its UroGen Pharma (URGN) position steady in Q2 2026 at 500,726 shares worth $18.4M. The position accounts for 0.06% of the portfolio, ranked #385.

Woodline Partners first reported a position in URGN in Q2 2024 and has held it in 9 quarters since. 189 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

Woodline Partners held 500,726 shares of UroGen Pharma worth $18.4M as of Q2 2026.
Woodline Partners left its UroGen Pharma share count unchanged in Q2 2026.
UroGen Pharma made up 0.06% of Woodline Partners's portfolio in Q2 2026, its #385 holding.
Woodline Partners first reported a position in UroGen Pharma in Q2 2024 and has held it in 9 quarters since.
189 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.